Significance: CRC patients with KRAS mutations are confronted with limited targeted therapeutic options. In this study, we have shown that the median survival time for KRAS -mutation mCRC patients with diabetes on metformin is 37.8 mo longer than those treated with other hypoglycemic drugs in combination with standard systemic therapy. Metformin is preferentially accumulated in KRAS -mutation CRC cells in both primary cell cultures and patient-derived xenografts. The promising therapeutic activity of metformin has a negative correlation with MATE1 expression, which is proven to eliminate metformin from CRC cells. These findings indicate that KRAS -mutation mCRC patients could benefit from metformin treatment, and somatic KRAS status or MATE1 expression should be recommended to predict the therapeutic response of metformin in CRC.
In the study of brain-computer interface, the EEG signal recognition classification method of motor imaging is one of the hot spots in today's research. In this study, we use frequency domain analysis based on the power spectrum density function to extract features from motor imagery EEG signals for two different motor imagery movements. We then combine with SVM to classify the features because BCI systems currently still have a low recognition rate accuracy. This study finds that employing the power spectrum in conjunction with SVM improves EEG signal classification when compared to alternative classifiers, such as random forest and convolutional neural networks. It can offer algorithmic assistance for the widespread use of BCI systems in everyday life.